Larry J. Siever
- PROFESSOR Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
MD, Stanford University School of Medicine
Residency, Internal Medicine
Mary's Help Hospital
Larry J. Siever is the director of the Special Evaluation Program for Mood and Personality Disorders, a Professor of Psychiatry, and Vice-Chair for VA Affairs at the Mount Sinai School of Medicine. He is also Director of the VISN 3 Mental Illness Research Education and Clinical Center and Chief of Psychiatry at the James J. Peters VA Medical Center. Dr. Siever is an internationally recognized leader in the field of personality disorder research. Throughout his career, his focus has been on the neurobiological substrates that underlie both borderline personality disorder and schizotypal personality disorder, and has published numerous articles and a book in this area. His present research employs neuroimaging techniques and cognitive enhancement to explore dopaminergic abnormalities in schizotypal personality disorder as part of the schizophrenia spectrum. His work in borderline personality disorder currently employs Positron Emission Tomography to identify specific receptor distribution in the brain that might underlie this pathology. He is also a well recognized teacher and clinician in the field of personality, as well as schizophrenia, affective, and impulse spectrum disorders.
New York Magazine
ResearchSpecific Clinical/Research Interests:
1)Cognitive impairment and cognitive augmentation in the schizophrenia spectrum.
2)Serotonergic genetics and pharmacology and aggression in personality disorders.
Postdoctoral Fellows: Daniel Rosell, MD and Lauren Helm,MD- borderline personality disorder, Joshua Kuluva, MD-traumatic brain injury, Christopher Cutter, PhD- mood and personality disorders
Summary of Research Studies:
1)Cognitive impairment and guanfacine treatment in schizotypal personality disorder.
2)Serotonergic imaging including serotonin transporter and 5HT2a receptor before and after fluoxetine treatment in aggressive personality disordered patients.
3)Dopaminergic interventions and cognitive impairment in schizotypal personality disorder.
4)Circuitry of affect regulation and impulsivity in borderline personality disorder.
5)Endophenotypes in borderline personality disorder. Endophenotypes in genetics of borderline and other personality disorder.
Infrastracture: The Mood and Personality Disorders Group is supported by a number of Federal grants both from NIMH and the VA as well as, Foundation funding and includes six faculty members, 8-10 research assistants, and 1 to 2 post-doctoral fellows, either/or both psychiatrist and psychologist. 50 to 100 patients are recruited each year, as are healthy controls for a variety of genetic testing, imaging, and pharmacologic studies.
Flory JD, Xu K, New AS, Finch T, Goldman D, Siever LJ. Irritable assault and variation in the COMT gene. Psychiatric Genetics 2007; 17: 344-346.
Minzenberg MJ, Xu K, Mitropoulou V, Harvey PD, Finch T, Flory JD, New AS, Goldman D, Siever LJ. Catechol-O-methyltransferase Val 158 Met genotype variation is associated with prefrontal dependent task performance in schizotypal personality disorder patients and comparison groups. Psychiatric Genetics 2006 Jun; 16(3): 117-124.
Koenigsberg HW, Buchsbaum MS, Buchsbaum BR, Schneiderman JS, Tang CY, New A, Goodman M, Siever LJ. Functional MRI of Visuospatial Working Memory in Schizotypal Personality Disorder: A Region - of - Interest Analysis. Psychol Med 2005; 35(7): 1019-1030.
Mitropoulou V, Harvey PD, Zegarelli G, New AS, Silverman JM, Siever LJ. Neuropsychological performance in schizotypal personality disorder: Importance of working memory. American J of Psychiatry 2005; 162(10): 1896-1903.
Frankle WG, Lombardo I, New AS, Goodman M, Talbot PS, Huang Y, Hwang DR, Slifstein M, Curry S, Abi-Dargham A, Laruelle M, Siever LJ. Brain Serotonin Transporters Distribution in Subjects with Impulsive aggressivity: A Positron Emission Study with [11C] McN5652. American Journal of Psychiatry 2005; 162(5): 915-923.
Siever LJ, Davis KL. The Pathophysiology of the Schizophrenic Disorders: Perspective from the Spectrum. American Journal of Psychiatry 2004;: 398-413.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Siever did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
1160 Fifth Avenue Floor Basement
New York, NY 10029
James J Peters Veteran Adminis Floor Routing No. 116A
130 West Kingsbridge Road
Bronx, NY 10468
1160 5th Avenue
Basement, Box 1230
New York, NY 10029
- Tuesday 4:30pm - 7:30pm
- Wednesday 4:30pm - 7:30pm
- Thursday 4:30pm - 7:30pm